Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout
An investor of rare disease treatment company Catalyst Pharmaceuticals Inc. is attempting to stop a buyout by Italian rival Angelini Pharma SpA, saying Catalyst's deficient proxy statement omits relevant information regarding...To view the full article, register now.
Already a subscriber? Click here to view full article